1 vial

$25.14

  • Reversal of the sedative effects of benzodiazepines

IV:
0.5mg/5ml of solution
Inject undiluted solution over 15 seconds preferably through a freely running IV infusion of compatible IV fluid and into a large vein.
For continuous infusion add 0.5mg to 50ml or 1mg to 100ml of compatible IV fluid (concentration 0.01mg/ml). Infuse at a rate of 0.1-0.4mg/hr (10-40ml/hr) and titrate to effect.
Compatible with the following IV fluids:
0.9% sodium chloride 5% glucose glucose and sodium chloride
Hartmanns


ADULT DOSE

IV:
Initially 0.2mg, followed by 0.1mg every 60 seconds as required to a maximum of 1mg
Note: in hepatic impairment initial dose remains the same but subsequent doses should be reduced in size or frequency

PAEDIATRIC DOSE

IV:
5mcg/kg every 60 seconds to a maximum total of 40mcg/kg then 2-10mcg/kg/hr

DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY
Dose as in normal renal function

Flumazenil, an imidazobenzodiazepine derivative, antagonizes the actions of benzodiazepines on the central nervous system. Flumazenil competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex.

CONTRAINDICATIONS:

  • Hypersensitivity to flumazenil or benzodiazepines

  • Benzodiazepine dependence


WARNINGS:
THE USE OF FLUMAZENIL HAS BEEN ASSOCIATED WITH THE OCCURRENCE OF SEIZURES. THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. PRACTITIONERS SHOULD INDIVIDUALISE THE DOSAGE OF FLUMAZENIL AND BE PREPARED TO MANAGE SEIZURES.

Flumazenil should be used with caution in the ICU because of the increased risk of unrecognised benzodiazepine dependence in such settings. Flumazenil may produce convulsions in patients physically dependent on benzodiazepines.

PRECAUTIONS
General
Risk of Seizures
The reversal of benzodiazepine effects may be associated with the onset of seizures in certain high-risk populations. Possible risk factors for seizures include: concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration in overdose cases, or concurrent cyclic anti-depressant poisoning.
Hypoventilation
Patients who have received flumazenil for the reversal of benzodiazepine effects (after conscious sedation or general anaesthesia) should be monitored for resedation, respiratory depression, or other residual benzodiazepine effects for an appropriate period (up to 120 minutes) based on the dose and duration of effect of the benzodiazepine employed.

Laboratory Tests:
No tests in addition to routine ICU tests are required.

Drug/Laboratory Test Interactions
None noted.

Particular caution is necessary when using flumazenil in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.

Body as a Whole:
Fatigue (asthenia, malaise), Headache, Injection Site Pain, Injection Site Reaction (thrombophlebitis, skin abnormality, rash).
Cardiovascular System:
Cutaneous vasodilation (sweating, flushing, hot flushes).
Digestive System:
Nausea and Vomiting.
Nervous System:
Agitation (anxiety, nervousness, dry mouth, tremor, palpitations, insomnia, dyspnea, hyperventilation), dizziness (vertigo, ataxia), emotional lability (crying abnormal, depersonalisation, euphoria, increased tears, depression, dysphoria, paranoia).
Special Senses:
Abnormal Vision (visual field defect, diplopia), Paraesthesia (sensation abnormal, hypoaesthesia).

[an error occurred while processing this directive]